US20080269730A1 - Ophthalmic Phototherapy Device and Associated Treatment Method - Google Patents
Ophthalmic Phototherapy Device and Associated Treatment Method Download PDFInfo
- Publication number
- US20080269730A1 US20080269730A1 US12/172,697 US17269708A US2008269730A1 US 20080269730 A1 US20080269730 A1 US 20080269730A1 US 17269708 A US17269708 A US 17269708A US 2008269730 A1 US2008269730 A1 US 2008269730A1
- Authority
- US
- United States
- Prior art keywords
- wavelength
- eye tissue
- light
- cornea
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001126 phototherapy Methods 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 60
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 230000001413 cellular effect Effects 0.000 claims abstract description 63
- 230000000694 effects Effects 0.000 claims abstract description 31
- 230000035876 healing Effects 0.000 claims abstract description 28
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 210000004087 cornea Anatomy 0.000 claims description 30
- 238000001356 surgical procedure Methods 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 16
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102000029816 Collagenase Human genes 0.000 claims description 9
- 108060005980 Collagenase Proteins 0.000 claims description 9
- 229960002424 collagenase Drugs 0.000 claims description 8
- 238000005520 cutting process Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims 8
- 230000004936 stimulating effect Effects 0.000 claims 4
- 230000007246 mechanism Effects 0.000 abstract description 11
- 210000001519 tissue Anatomy 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 20
- 230000009286 beneficial effect Effects 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 230000037319 collagen production Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002430 laser surgery Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
- A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/14—Arrangements specially adapted for eye photography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/0079—Methods or devices for eye surgery using non-laser electromagnetic radiation, e.g. non-coherent light or microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00868—Ciliary muscles or trabecular meshwork
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00872—Cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00885—Methods or devices for eye surgery using laser for treating a particular disease
- A61F2009/00891—Glaucoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0644—Handheld applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
Abstract
An ophthalmic phototherapy device and associated phototherapy treatment method for promoting healing of damaged or diseased eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue. The ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.
Description
- This application is a Continuation-In-Part of U.S. application Ser. No. 11/106,416, filed Apr. 14, 2005; and a Continuation-In-Part of U.S. application Ser. No. 11/858,351, filed Sep. 20, 2007.
- Not Applicable
- 1. Field of Invention
- This invention relates to an ophthalmic phototherapy device and an associated treatment method. More specifically, the present invention is related to a device and method for exposing an eye to selected wavelengths of light to promote the healing of damaged eye tissue.
- 2. Description of the Related Art
- Light has various uses within the medical community. Exposure of cellular tissue to light is known to modulate the activity of such cellular tissue. Different wavelengths of light act on different mechanisms within individual cells within the cellular tissue to stimulate or suppress biological activity within the cells in a process commonly referred to as photobiomodulation. In certain photobiomodulation applications, commonly known as light therapy or phototherapy, the different wavelengths are used to promote healing, revitalize and rejuvenate cells, and in some circumstances, stimulate cellular regeneration and regrowth.
- Molecules like cytochrome-C oxidase, hemoglobin, myoglobin, and nicotinamide adenine dinucleotide (NADH), found in cellular tissue, are recognized as photon acceptors and serve to initiate biochemical cellular response to photons. Additionally, it is recognized that certain biologic quantum field effects result from exposing cellular tissue to photonic light and that living cells generate low levels of photons, called biophotons. These biophotons are non-thermal in nature and are coupled to physiological functions in the cellular tissue. Biophotons represent regulatory activity from chemical reactivity within a cell and also perform regulatory activity over a given cellular tissue to promote cell growth and differentiation, and to provide intercellular and intracellular communication, such as for example, synchronicity in biofunction between cells. Such biophotons within a cellular tissue can be simulated by photonic light of one or more specific wavelengths from a source external to the cellular tissue. Such photonic light, when exposed to the cellular tissue, results in promotion of regulatory activity within the cells of the exposed cellular tissue.
- Thus, it is generally accepted that cell activity can be up-regulated and down-regulated by specific wavelengths of low intensity light. The up- and down-regulation of cell activity through photobiomodulation is used to suppress cytokines, block the matrix metalloproteinases (MMP) cascade, suppress interleukins (IL) and tissue necrosis factors, and decreasing inflammation of cellular tissue. Photobiomodulation is also used to affect mitochondrial density and activity, cell proliferation and adhesiveness, and DNA and RNA production. Phototherapy has been shown to affect vascular endothelial growth factor (VEGF) expression (both enhancement and suppression) and to protect against a wide variety of toxins, such as chemical, ionizing, and bacteriologic toxins.
- At least some of the known effects of the various wavelengths on body tissues are as follows. Light in the yellow range (approximately 577 nm to 597 nm) has been shown to switch off collagenase production by down-regulating MMPs and switching on new collagen production. Collagenases are enzymes that break down the native collagen that holds animal tissue together. Thus, use of light in the yellow range for phototherapy ultimately results in increased cohesion of cells in animal tissue. Light in the red range (approximately 640 nm to 700 nm) has been shown to decrease inflammation in injured tissue, increase ATP production, and otherwise stimulate beneficial cellular activity. Light in the blue range (approximately 405 nm to 450 nm) has been shown to kill various microorganisms. For example, light in the blue range has been shown to kill the propionibacterium that causes acne by activating the porphyrins produced by the bacteria. Accordingly, phototherapy has been utilized to treat infants for jaundice (e.g., U.S. Pat. No. 6,811,563), to treat acne and other skin conditions (e.g., U.S. Pat. No. 6,387,089), to treat rhinitis (e.g., U.S. Pat. No. 5,683,436), and to treat traumatic tissue injuries (e.g. U.S. Pat. No. 6,471,716).
- Photobiomodulation also requires the use of light with suitable intensity, energy, and wavelengths, the combination of which allows light of the selected wavelengths to penetrate the cellular tissue and activate the desired cellular mechanism without significantly causing damage to the cells. The combination of characteristics suitable for photobiomodulation applications are distinct from those of light used in other applications. Other applications use high-energy, high-intensity light sources, e.g., excimer lasers, that are destructive as opposed to regenerative, because the light emitted is so intense that, as the laser light penetrates the cellular tissue, the cells become burned, melted, or otherwise destroyed. General purpose lighting, such as an incandescent light, uses low-energy light sources ranging in intensity that is incapable of sufficiently penetrating the cellular tissue, which results in superficial exposure of the cellular tissue to the low-energy light and, therefore, reduced photobiomodulation effects. Further, an incandescent light produces numerous wavelengths and the wavelengths are not subject to independent control, which results in unpredictable modulation of the cellular activity within the exposed cellular tissue. High-intensity light of sufficient energy to properly penetrate the cellular tissue and initiate photobiomodulation tends to burn and/or melt the cellular tissue prior to the completion of a phototherapy treatment. Hence, light appropriate for use in phototherapy should exhibit both a relatively low intensity, so as not to destroy the exposed cells, and a relatively high energy, so as to allow for sufficient penetration of light into the exposed cellular tissue such that the activities of a desired portion of cells within the exposed cellular tissue are photobiomodulated.
- One device which is known to produce relatively low-intensity, high-energy light suitable for use in phototherapy is the light-emitting diode (LED). Several commercial phototherapy devices are available including devices which utilize LEDs, including the Gentlewaves® LED Photomodulation Device manufactured by Light BioScience, LLC, which includes a panel of LEDs for treating skin conditions, and the Flip4 Max7 LED device which incorporates an LED panel capable of producing multiple wavelengths of light, and which is also marketed for treating skin conditions. Further, the U.S. military and NASA have utilized small hand-held devices incorporating LED arrays that are used to reduce inflammation and to promote healing in damaged skin tissue. Light from such LED devices has been shown to exhibit the low-intensity and high-energy characteristics appropriate for use in photobiomodulation.
- Various laser devices have been used in the field of opthalmology for the purposes of ablating and cutting eye tissue during laser-assisted surgery on an eye. Likewise, various laser devices have been used to melt or otherwise liquefy eye tissue surrounding a surgical wound in order to establish a weld or other such seal in the surgical wound. However, in order to fix certain eye problems, these destructive uses of light cause other damage to the eye tissue, but this damage is of the type that can be healed by the body's normal recuperative mechanisms over time. In addition, a device using LEDs has been utilized in the field of opthalmology in an effort to strengthen corneal tissue. However, this device utilizes LEDs producing wavelengths falling in the middle to far ultraviolet ranges (approximately 100 nm to 300 nm) to induce cross-linking of corneal collagen and thereby stiffen the cornea of the eye. Thus, this process, in effect, ages the corneal tissue, as opposed to facilitating the production of new, “normal” tissue. Therefore, the process is not one in which healing of eye tissue is promoted. Accordingly, none of the known phototherapy mechanisms are used for promoting the healing, regrowth, or regeneration of eye tissue or for alleviating discomfort associated with damaged eye tissue within the field of opthalmology.
- The present invention provides an ophthalmic phototherapy device, and an associated phototherapy method, for promoting healing of damaged eye tissue. The ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the damaged eye tissue, whereby the light transmitted to the eye tissue stimulates activity in the eye tissue to promote healing. The light emitting mechanism can include a light panel having a plurality of light emitting diodes (LEDs) for emitting light. In one embodiment the device has a first set of LEDs capable of emitting light having a first wavelength, and at least a second set of LEDs capable of emitting light having a second wavelength. Further, a controller is provided for selectively controlling which LEDs are energized at any given time, such that different sequences and/or combinations of light wavelengths can be selectively communicated to the eye tissue being treated.
- The ophthalmic phototherapy method of the present invention includes identifying a treatable portion of cellular tissue in an eye. The identified portion of damaged eye tissue is exposed to light of at least one preselected wavelength for a preselected period of time to photobiomodulate cellular activity in the cellular tissue to promote healing. Further, in one application of the method, the tissue is exposed to light of a plurality of wavelengths either sequentially, or in combination.
- The above-mentioned features of the invention will become more clearly understood from the following detailed description of the invention read together with the drawings in which:
-
FIG. 1 is a perspective view of an ophthalmic phototherapy device of the present invention; -
FIG. 2 is a front elevation view of an ophthalmic phototherapy device ofFIG. 1 ; -
FIG. 3 is a perspective view of another embodiment of an ophthalmic phototherapy device of the present invention; -
FIG. 4 is a side elevation view of another embodiment of an ophthalmic phototherapy device of the present invention, showing the ophthalmic phototherapy device mounted on a slit lamp; -
FIG. 5 is a block diagram of a power/control system for an ophthalmic phototherapy device of the present invention; and -
FIG. 6 is a flow diagram showing one embodiment of the method of the present invention. - An ophthalmic phototherapy device is illustrated generally at 10 in the drawings. As will be discussed in detail below, the
ophthalmic phototherapy device 10 produces light of a selected wavelength, or sequences or combinations of light having differing wavelengths within a particular range of wavelengths. In accordance with the ophthalmic treatment method of the present invention, the light emitted by thephototherapy device 10 is directed into the eye of a patient to promote healing of damaged eye tissue. -
FIG. 1 illustrates one embodiment of theophthalmic phototherapy device 10. Theophthalmic phototherapy device 10 incorporates a light emitting mechanism that includes alight panel 12 incorporating a plurality oflight sources 14 that emit light having the desired wavelengths. Thelight panel 12 is mounted in ahousing 16 that is configured to facilitate use of thedevice 10. Aswitch 20 allows the operator to control the production of light. In one embodiment, the light sources are LEDs. It will be appreciated that other mechanisms capable of emitting light of a desired wavelength, intensity, and energy can be used, and that the use of theterm LEDs 14 throughout the application is not intended to limit the available mechanisms for producing the desired light. For example, the light emitting mechanism could include a low power laser source for generating light of the appropriate wavelength(s), or one or more filtered incandescent or fluorescent lights. In the illustrated embodiment, theophthalmic phototherapy device 10 is configured for hand-held use. However, those skilled in the art will recognize that the ophthalmic phototherapy device can be either hand-held or mounted on an operatively associated medical device or other supporting structure without departing from the scope and spirit of the present invention. -
FIG. 2 is an front elevation view of thephototherapy device 10. With respect to the particular LEDs used in thepanel 12, and as will be discussed further below, one approximate range of wavelengths desirable for ophthalmic phototherapy is between 300 nm and 1000 nm. However, other wavelengths may be beneficial for certain applications. Thus, depending on the particular therapeutic application, thepanel 12 can be configured to have a plurality ofLEDs 14 that produce the same wavelength of light within a desired range, or thepanel 12 can incorporate selected combinations ofLEDs 14 capable of producing light of differing wavelengths within a desired range. As will be discussed further below, where selected combinations ofLEDs 14 are used which produce different wavelengths, the operator of thedevice 10 can select among wavelengths to be emitted within a desired range. Alternatively, where the ability to select between the wavelengths of the light emitted is desired, thepanel 12 could incorporateLEDs 14 that produce a common wavelength and conventional filters (not shown) could be used to alter the wavelength to that desired. - In
FIG. 3 an alternate embodiment of the ophthalmic phototherapy device of the present invention is illustrated at 10′. It will be noted that features of thedevice 10′ that are common to thedevice 10 are referenced with common prime numerals. Those skilled in the art will recognize that certain hand-held ophthalmic instruments, such as retinoscopes and opthalmoscopes, utilize interchangeable, detachable handles which incorporate rechargeable batteries. Theophthalmic phototherapy device 10′ includes ahousing 16′ that detachably couples with such an interchangeable,rechargeable battery handle 22. Thus, thedevice 10′ utilizes a power supply which is commonly available to ophthalmic health care professionals, and does not require a recharging system that is unique to the phototherapy device. - A further alternate embodiment of the ophthalmic phototherapy device of the present invention is illustrated at 10″ in
FIG. 4 . In this regard, it will be noted that features of thedevice 10″ that are common to thedevice 10 are referenced with common double prime numerals. As illustrated, theophthalmic phototherapy device 10″ includes an articulatedarm 24 that allows thedevice 10″ to be adjustably mounted on a piece of operatively associated ophthalmic equipment such as the illustratedslit lamp 26. Although, thedevice 10″ is illustrated as being mounted on aslit lamp 26 inFIG. 4 , it will be understood that thedevice 10″ could be mounted on various other pieces of equipment or structures. For example, and as will be discussed further below, in one embodiment, thedevice 10″ is mounted proximate the head of an excimer laser such thatdevice 10″ can be utilized immediately before, during and/or after laser eye surgery. - Whereas the articulated
support arm 24 defines various jointed configurations which allow thedevice 10″ to be selectively positioned at various locations while being supported on associated ophthalmic equipment or other structures, the illustratedarm 24 includes afirst arm section 28 having first andsecond end portions first end portion 30 is pivotally secured to theslit lamp 26 or other supporting structure, such that thearm 24 can be selectively pivoted in a substantially horizontal plane. Thesecond end portion 32 of thefirst arm section 28 is pivotally secured to thefirst end portion 36 of asecond arm section 34 such that thesecond arm section 34 pivots in a substantially vertical plane. Further, thesecond arm section 34 is pivotally secured proximate itssecond end portion 38 to abracket 40 provided on thehousing 16″ such that thehousing 16″ and thelight panel 12″ pivot in a substantially vertical plane which is substantially perpendicular to the plane in which thesecond arm section 34 pivots. - It will be recognized that various mechanisms could be used for pivotally securing the
first arm section 28 to a supporting structure, for pivotally securing thefirst arm section 28 to thesecond arm section 34, and for pivotally securing thesecond arm section 34 to thebracket 40. However, as illustrated inFIG. 4 , in one embodiment anattachment structure 42 is provided that is secured to the supporting structure, as by an adhesive or by mechanical fasteners (not shown), and a threadedfastener 44 having a lockingknob 48 is used to pivotally, and lockably, secure thefirst end portion 30 of thefirst arm section 28 to theattachment structure 42. A second threadedfastener 50 having a lockingknob 52 is provided for pivotally, and lockably, securing thesecond arm section 34 to thefirst arm section 28, and a third threadedfastener 54, with a lockingknob 56, is provided for pivotally, and lockably, securing thesecond arm section 34 to thebracket 40. Thus, it will be recognized that the articulatedsupport arm 24 allows thelight panel 12″ to be pivoted to a position where it does not interfere with the use of the equipment on which it is mounted, and allows thelight panel 12″ to be pivoted into position to emit light into the eye of a patient when needed. Whereas theophthalmic phototherapy device 10 anddevice 10′ could be used in conjunction with laser eye surgery, it will be recognized that use of thedevice 10″ with its articulatedsupport arm 24 is particularly advantageous. In this regard, the articulatedsupport arm 24 allows thedevice 10″ to be mounted proximate a laser surgery apparatus such that both immediately prior to and immediately following the surgical procedure, thepanel 12 can be rotated into position to emit light into the eye to promote healing. -
FIG. 5 illustrates a block diagram of theophthalmic phototherapy device 10. Theophthalmic phototherapy device 10 includes apower supply 18 for energizing thelight panel 12 in response to operation of theswitch 20 for which selectively connects and disconnects thelight panel 12 and thepower supply 18 to turn thepanel 12 on and off. In one embodiment, the power supply is a battery (not shown) that is preferably rechargeable. In other embodiments, suitable circuitry is provided for connecting the device to a conventional AC power supply such as a wall outlet. In addition, as will be discussed below with respect to the phototherapy method of the present invention, several embodiments of theophthalmic phototherapy device 10 allow selective control of the wavelength of the light emitted by thedevice 10, as well as the duration of a patient's exposure to the light emitted, and the energy and intensity of the light emitted. Accordingly, theophthalmic phototherapy device 10 illustrated inFIG. 5 includes a power/control system 58 that includes acontroller 60 for activating and/or deactivating the LEDs. In several embodiments, thecontroller 60 includes a timer for automatically turning the LED's off after a preselected period of time. Thecontroller 60 also controls the energy output of theLEDs 14 and the intensity of the output light, and, whereLEDs 14 emitting light of different wavelengths are used, which LEDs are lit at any given time. Further, in another embodiment thecontroller 60 allows different LEDs to be lit in a desired sequence, or in a pulsed format. In one embodiment, the controller is implemented in discrete circuits, either analog or digital, designed to perform the various functions. In another embodiment, the controller is implemented using any processor device or other similar device providing the necessary logic and control functions. - Referring to
FIG. 6 , thephototherapy method 76 of the present invention includes generally identifying a treatable portion of cellular tissue in aneye 62, such as a damaged portion of cellular tissue, or a portion of cellular tissue in which imminent damage is anticipated. Once a treatable portion of cellular tissue is identified, treatment is performed 74 by directing light of at least one preselected wavelength to cells forming at least a portion of the cellular tissue to be treated. The wavelength composition of the light directed to the cellular tissue during treatment is preselected so that exposure of the cellular tissue to the light results in photobiomodulation of the cellular activity of at least a portion of the cells forming the cellular tissue, such that healing of the cellular tissue is promoted. - The approximate range of wavelengths desirable for ophthalmic phototherapy correspond to portions of the visible and invisible infrared spectrum ranging from blue light to near-infrared and infrared light, in other words, light having wavelengths between approximately 300 nm and 1000 nm, and preferably between 490 nm and 810 nm. However, both the general and preferred ranges are not intended to be limiting as wavelengths outside of these ranges may be helpful for certain treatment applications. The particular wavelength used varies depending on the injury or eye condition being treated. For example, light in the yellow range (approximately 577 nm to 597 nm) has been shown to switch off collagenase production by down-regulating MMP production and to switch on new collagen production. In the field of opthamology, yellow light having a wavelength of approximately 590 nm has been found to be beneficial for treating corneal trauma when directed into a traumatized cornea. Red light (approximately 640 nm to 700 nm) has been found to decrease inflammation of tissue in the eye, increase ATP production, and reset cellular activity to cause abnormal cells to exhibit more normal behavior. Further, a preselected sequence or combination of wavelengths can be advantageously used in certain conditions. For example, a sequence or combination of infrared or near-infrared light, red light, and yellow light directed into the eye at a dosage of approximately 4 joules/sq. cm has been found to be beneficial for treating glaucoma. Similar dosages of sequences or combinations of infrared or near-infrared light, red light, and yellow light have been found to stimulate the cells in the trabecular meshwork to produce macrophages that then reduce the pigment cells clogging the meshwork of the eye, thereby allowing the eye to drain.
- The duration of the phototherapy treatments varies depending on the particular eye condition being treated. Beneficial tissue response can be obtained from dosages of less than 4 joules/sq. cm, such that the duration of treatment can be relatively short. Exposure times of less than one minute can be beneficial, with exposure times in excess of 10 minutes being contemplated. For example, to achieve approximate dosages of less than 4 joules/sq. cm, treatment duration could vary between under a minute to approximately 10 minutes, depending upon the output power and intensity of the light source utilized. Further, although phototherapy treatments of less than 0.1 joules/sq. cm, and having durations of 40 seconds or less, have been shown to be beneficial, longer treatments may be desirable to provide additional benefit, or to allow for larger dosages of light energy per unit area of cellular tissue. Of course, it will be understood by one skilled in the art that beneficial tissue response can be obtained from dosages of light energy greater than 4 joules/sq. cm, and such dosages may be used without departing from the spirit and scope of the present invention.
-
FIG. 6 is a block diagram of onemethod 76 for promoting healing of eye tissue. In the illustrated embodiment, the method begins with awavelength selection step 78, involving the selection of one or more wavelengths of light for use in themethod 76. As discussed above, the particular wavelengths selected for use depends upon the desired cellular activity to be stimulated through application of themethod 76. For example, in one embodiment, wavelengths in the red and near-infrared spectrums are selected to suppress inflammation of the eye tissue. In another embodiment, wavelengths in the yellow spectrum are selected to suppress collagenase production and to stimulate new collagen production. In still another embodiment, wavelengths in multiple color spectrums are selected to stimulate multiple desired cellular activities in the treated eye tissue. - In a
dosage selection step 80, a suitable dosage of light is selected for use in themethod 76 for the selected wavelength. In the illustrated embodiment, selection of thedosage 80 includes selection of amount oflight energy 82 to be delivered over a selected period oftime 84 at a selectedintensity 86. However, it will be understood that other factors, such as for example the topical area of cellular tissue to be treated, diffusion of the light to be applied, and other such factors, may be selected during the selection ofdosage 80 without departing from the spirit and scope of the present invention. A light source is provided which is capable of generating a beam of light having the characteristics selected during thedosage selection step 80. At atreatment phase 74, the light source is used to generate a beam of light 88 having the characteristics selected during thedosage selection step 80. In the illustrated embodiment, a beam of light is generated 88 having the energy, duration, and intensity characteristics selected in thedosage selection step 80. Of course, it will be understood that the particular characteristics of the generated beam of light depend upon the specific factors selected during thedosage selection step 80. At adirection step 90, the beam oflight 88 is directed to a portion of eye tissue to be treated. Upon exposure of cells in the eye tissue to the beam oflight 88, at least a portion of the cells are stimulated to undergo at least one desired cellular activity corresponding to the selected wavelength. In this way, cellular activity useful in promotion of healing of the eye tissue is stimulated. - In another embodiment, illustrated in
FIG. 7 , themethod 76′ is used for promoting healing of eye tissue both before and after performing a medical procedure on the eye to correct vision problems. In the illustrated embodiment, the method begins with an optional pretreatmentdosage selection step 92, wherein a dosage is selected for anoptional pretreatment step 72. Thepretreatment step 72 involves directing light of one or more selected wavelengths of selected energy, duration, and intensity characteristics into the cornea of the patient's eye in order to stimulate the eye tissue to engage in cellular activity beneficial to healing. In one embodiment, the light uses wavelengths in the red and near-infrared spectrums to suppress inflammation of the eye tissue during and after surgery. In another embodiment, the light used in thepretreatment step 72 uses wavelengths in both the yellow and red spectrums to suppress inflammation of the eye tissue during and after surgery, to suppress collagenase production, and to stimulate new collagen production. - In a
damage phase 62, a medical procedure for correcting vision problems is performed, thereby damaging a portion of eye tissue. The medical procedure of the illustrated embodiment uses laser surgery of the epithelium and stroma portions of the cornea of the eye, a laser-assisted in situ keratomileusis procedure commonly referred to as LASIK eye surgery as an example. The LASIK procedure involves thestep 64 of cutting a flap in the epithelium of the cornea of an eye while leaving the eye tissue at one end of the flap uncut. It will be appreciated by those familiar with LASIK that a knife, referred to as a microkeratome, or a laser, such as the IntraLase™ femtosecond (1054 nm) laser, can be used to cut theflap 64. In afolding step 66, the uncut tissue serves as a hinge that allows the flap to be folded back to reveal the stroma, or middle section of the cornea. A reshapingstep 68 uses pulses from a computer controlled excimer laser to vaporize a portion of the stroma and reshape the cornea. The LASIK procedure ends with aflap replacement step 70 in which the flap of epithelium tissue is replaced 70. - To this extent, in the illustrated embodiment, the
damage phase 62 includes performing LASIK eye surgery on an eye. However, while the embodiment of the method inFIG. 7 illustrates the performance of laser eye surgery at thedamage phase 62, it will be understood that the phototherapy method of the present invention can also be beneficially used to promote healing of eye tissue in connection with various other eye conditions. For example, themethod 76′ is also effective in promoting healing in connection with LASIK or Epi-Lasik procedures, corneal inlays, corneal transplants (penetrating keratoplasty or PKP), cataract and intraocular implant (IOL) surgery, and glaucoma surgery. Utilized during or after such procedures, the present phototherapy method reduces healing time and the need for extended use of postoperative drugs such as steroids. Moreover, the phototherapy method of the present invention is useful in promoting healing of damaged eye tissue whether the damage is the result of disease, accident, surgery, or other such occurrences. To this extent, in another embodiment, thedamage phase 62 is accomplished by allowing a portion of cellular tissue in an eye to become damaged or diseased. - Following the
damage phase 62, a treatmentdosage selection step 80 is performed. As discussed above, selection of thetreatment dosage 80 includes selection of an amount of light energy to be delivered over a selected period of time at a selected intensity. In atreatment step 74, light of a selected wavelength is directed into the cornea of the patient's eye in accordance with the selectedtreatment dosage 80 for photobiomodulating the damaged eye tissue to promote healing and suppress inflammation. - Whereas numerous wavelengths are beneficial during the optional
initial step 72, the yellow range of wavelengths (approximately 577 nm to 597 nm) is particularly beneficial fortreatment 74 of the eye tissue after laser eye surgery. Thus, in one embodiment, the light directed into the patient'seye 72 subsequent to replacement of theepithelial flap 70 is preselected to exhibit a wavelength in the yellow spectrum, having a range of approximately 577 nm and 597 nm. In another embodiment, the light directed into the patient'seye 72 subsequent to replacement of theepithelial flap 70 is preselected to exhibit a wavelength between the range of approximately 577 nm and 1000 nm. In more discreet embodiments, the light directed into the patient'seye 72 followinglaser surgery 62 is preselected to exhibit multiple wavelengths in the yellow light spectrum, having ranges of between approximately 577 nm to 597 nm, and the red and near-infrared spectrum, having ranges between approximately 640 nm to 1000 nm. - In light of the above, it will be recognized that the
ophthalmic phototherapy devices ophthalmic phototherapy device 10″, with its articulatedsupport arm 24, can be particularly useful in applying phototherapy in accordance with thepresent method 76′ subsequent tolaser eye surgery 62. In this regard, the articulatedsupport arm 24 allows thepanel 12″ to be rotated into position to emit light into the patient's eye immediately upon completion of the surgical procedure. - While the present invention has been illustrated by description of several embodiments and while the illustrative embodiments have been described in considerable detail, it is not the intention of the applicant to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. The invention in its broader aspects is therefore not limited to the specific details, representative apparatus and methods, and illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of applicant's general inventive concept.
Claims (20)
1. An ophthalmic phototherapy method for stimulating desired cellular activity useful in promoting the healing of damaged eye tissue, said method comprising the steps of:
(a) selecting a wavelength for treatment of the damaged eye tissue, said wavelength adapted to cause activation of a desired cellular activity in the damaged eye tissue;
(b) selecting a dosage for treatment of the damaged eye tissue, said dosage comprising a selected energy delivered over a selected period of time at a selected intensity for said selected wavelength, said selected energy being sufficient to penetrate into the damaged eye tissue, said selected intensity being low enough to minimize further damage to the damaged eye tissue;
(c) providing a light source adapted to produce a beam of light having said selected wavelength, said selected energy, and said selected intensity for said selected period of time;
(d) generating said beam of light; and
(e) directing said beam of light at the damaged eye tissue according to said selected dosage;
whereby the activation of desired cellular activity useful in healing of the damaged eye tissue is promoted.
2. The ophthalmic phototherapy method of claim 1 , wherein said wavelength is between approximately 300 nm and approximately 1000 nm.
3. The ophthalmic phototherapy method of claim 1 , wherein said wavelength is between approximately 577 nm and approximately 597 nm.
4. The ophthalmic phototherapy method of claim 1 , wherein said wavelength is selected to activate a decrease in production of collagenase in the damaged eye tissue.
5. The ophthalmic phototherapy method of claim 1 , wherein said wavelength is selected to activate a decrease in inflammation of cellular tissue in the damaged eye tissue.
6. An ophthalmic phototherapy method for stimulating desired cellular activity useful in promoting the healing of damaged eye tissue, said method comprising the steps of:
(a) selecting a first wavelength for pretreatment of eye tissue, said first wavelength adapted to cause activation of a first desired cellular activity in the eye tissue;
(b) selecting a first dosage for pretreatment of the eye tissue, said first dosage comprising a first selected energy delivered over a first selected period of time at a first selected intensity for said first selected wavelength, said first selected energy being sufficient to penetrate into the eye tissue, said first selected intensity being low enough to minimize damage to the eye tissue;
(c) providing a light source adapted to produce a first beam of light having said first selected wavelength, said first selected energy, and said first selected intensity for said first selected period of time;
(d) generating said first beam of light;
(e) pretreating at least a portion of the eye tissue by directing said first beam of light at the eye tissue according to said first selected dosage;
(f) allowing at least a portion of the cellular tissue to become damaged;
(g) selecting a second wavelength for treatment of the damaged eye tissue, said second wavelength adapted to cause activation of a second desired cellular activity in the damaged eye tissue;
(h) selecting a second dosage for treatment of the damaged eye tissue, said second dosage comprising a second selected energy delivered over a second selected period of time at a second selected intensity for said second selected wavelength, said second selected energy being sufficient to penetrate into the damaged eye tissue, said second selected intensity being low enough to minimize further damage to the damaged eye tissue;
(i) providing a light source adapted to produce a second beam of light having said second selected wavelength, said second selected energy, and said second selected intensity for said second selected period of time;
(j) generating said second beam of light; and
(k) treating at least a portion of the eye tissue by directing said second beam of light at the damaged eye tissue according to said second selected dosage;
whereby the activation of desired cellular activity useful healing of the damaged eye tissue is promoted.
7. The ophthalmic phototherapy method of claim 6 , wherein said step of allowing the eye tissue to become damaged includes performing laser eye surgery on the eye, thereby damaging the cornea of the eye.
8. The ophthalmic phototherapy method of claim 6 wherein each of the first and second selected wavelengths is between approximately 300 nm and approximately 1000 nm.
9. The ophthalmic phototherapy method of claim 6 wherein the first wavelength is selected to be between approximately 640 nm and approximately 700 nm, and wherein the second wavelength is selected to be between approximately 577 nm and approximately 597 nm.
10. The ophthalmic phototherapy method of claim 6 , wherein said first wavelength is selected to activate a decrease in inflammation of the eye tissue.
11. The ophthalmic phototherapy method of claim 6 , wherein said second wavelength is selected to activate a decrease in production of collagenase in the damaged eye tissue.
12. The ophthalmic phototherapy method of claim 6 , wherein said second wavelength is selected to activate a decrease in inflammation of cellular tissue in the damaged eye tissue.
13. An ophthalmic phototherapy method for stimulating desired cellular activity useful in promoting the healing of a cornea of an eye following laser eye surgery, said method comprising the steps of:
(a) selecting a first wavelength for pretreatment of the cornea, said first wavelength adapted to cause activation of a first desired cellular activity in the cornea;
(b) selecting a first dosage for pretreatment of the cornea, said first dosage comprising a first selected energy delivered over a first selected period of time at a first selected intensity for said first selected wavelength, said first selected energy being sufficient to penetrate into the cornea, said first selected intensity being low enough to minimize damage to the cornea;
(c) providing a light source adapted to produce a first beam of light having said first selected wavelength, said first selected energy, and said first selected intensity for said first selected period of time;
(d) generating said first beam of light;
(e) pretreating the cornea by directing said first beam of light at the cornea according to said first selected dosage;
(f) cutting a flap in the cornea and folding back the flap to reveal the stroma of the cornea;
(g) using a laser to vaporize a portion of the stroma to facilitate the reshaping of the cornea;
(h) replacing the flap;
(g) selecting a second wavelength for treatment of the cornea, said second wavelength adapted to cause activation of a second desired cellular activity in the cornea;
(h) selecting a second dosage for treatment of the cornea, said second dosage comprising a second selected energy delivered over a second selected period of time at a second selected intensity for said second selected wavelength, said second selected energy being sufficient to penetrate into the cornea, said second selected intensity being low enough to minimize further damage to the cornea;
(i) providing a light source adapted to produce a second beam of light having said second selected wavelength, said second selected energy, and said second selected intensity for said second selected period of time;
(j) generating said second beam of light; and
(k) treating the cornea by directing said second beam of light at the cornea according to said second selected dosage;
whereby the activation of desired cellular activity useful healing of the cornea is promoted.
14. The ophthalmic phototherapy method of claim 13 wherein each of the first and second wavelengths is selected to be between approximately 300 nm and approximately 1000 nm.
15. The ophthalmic phototherapy method of claim 14 wherein the first wavelength is selected to be between approximately 640 nm and approximately 700 nm, and wherein the second wavelength is selected to be between approximately 577 nm and approximately 597 nm.
16. The ophthalmic phototherapy method of claim 13 , wherein said step of treating at least a portion of the cornea includes stimulating at least a portion of cells in the cornea to decrease inflammation of the cellular tissue.
17. The ophthalmic phototherapy method of claim 13 , wherein said first wavelength is selected to activate a decrease in production of collagenase in the damaged eye tissue.
18. The ophthalmic phototherapy method of claim 13 , wherein said first wavelength is selected to activate a decrease in inflammation of the eye tissue.
19. The ophthalmic phototherapy method of claim 13 , wherein said second wavelength is selected to activate a decrease in production of collagenase in the damaged eye tissue.
20. The ophthalmic phototherapy method of claim 13 , wherein said second wavelength is selected to activate a decrease in inflammation of cellular tissue in the damaged eye tissue.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/172,697 US20080269730A1 (en) | 2005-04-14 | 2008-07-14 | Ophthalmic Phototherapy Device and Associated Treatment Method |
US13/679,557 US20130079759A1 (en) | 2005-04-14 | 2012-11-16 | Ophthalmic Phototherapy Device and Associated Treatment Method |
US15/050,484 US20160166850A1 (en) | 2005-04-14 | 2016-02-23 | Ophthalmic phototherapy device and associated treatment method |
US15/050,482 US9592404B2 (en) | 2005-04-14 | 2016-02-23 | Ophthalmic phototherapy device and associated treatment method |
US15/050,483 US9592405B2 (en) | 2005-04-14 | 2016-02-23 | Ophthalmic phototherapy device and associated treatment method |
US15/081,805 US9782604B2 (en) | 2005-04-14 | 2016-03-25 | Ophthalmic phototherapy device and associated treatment method |
US15/497,148 US9814903B2 (en) | 2005-04-14 | 2017-04-25 | Ophthalmic phototherapy system and associated method |
US15/783,666 US9974971B2 (en) | 2005-04-14 | 2017-10-13 | Ophthalmic phototherapy method |
US15/957,496 US10252078B2 (en) | 2005-04-14 | 2018-04-19 | Ophthalmic phototherapy method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/106,416 US20060235493A1 (en) | 2005-04-14 | 2005-04-14 | Ophthalmic phototherapy device and associated treatment method |
US11/858,351 US7479136B2 (en) | 2005-04-14 | 2007-09-20 | Ophthalmic phototherapy treatment method |
US12/172,697 US20080269730A1 (en) | 2005-04-14 | 2008-07-14 | Ophthalmic Phototherapy Device and Associated Treatment Method |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/858,351 Continuation-In-Part US7479136B2 (en) | 2005-04-14 | 2007-09-20 | Ophthalmic phototherapy treatment method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/679,557 Continuation-In-Part US20130079759A1 (en) | 2005-04-14 | 2012-11-16 | Ophthalmic Phototherapy Device and Associated Treatment Method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080269730A1 true US20080269730A1 (en) | 2008-10-30 |
Family
ID=46330318
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/172,697 Abandoned US20080269730A1 (en) | 2005-04-14 | 2008-07-14 | Ophthalmic Phototherapy Device and Associated Treatment Method |
US15/081,805 Active US9782604B2 (en) | 2005-04-14 | 2016-03-25 | Ophthalmic phototherapy device and associated treatment method |
US15/497,148 Active US9814903B2 (en) | 2005-04-14 | 2017-04-25 | Ophthalmic phototherapy system and associated method |
US15/783,666 Active US9974971B2 (en) | 2005-04-14 | 2017-10-13 | Ophthalmic phototherapy method |
US15/957,496 Active US10252078B2 (en) | 2005-04-14 | 2018-04-19 | Ophthalmic phototherapy method |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/081,805 Active US9782604B2 (en) | 2005-04-14 | 2016-03-25 | Ophthalmic phototherapy device and associated treatment method |
US15/497,148 Active US9814903B2 (en) | 2005-04-14 | 2017-04-25 | Ophthalmic phototherapy system and associated method |
US15/783,666 Active US9974971B2 (en) | 2005-04-14 | 2017-10-13 | Ophthalmic phototherapy method |
US15/957,496 Active US10252078B2 (en) | 2005-04-14 | 2018-04-19 | Ophthalmic phototherapy method |
Country Status (1)
Country | Link |
---|---|
US (5) | US20080269730A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9555111B2 (en) | 2012-03-29 | 2017-01-31 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US9592405B2 (en) | 2005-04-14 | 2017-03-14 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy device and associated treatment method |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US20170143442A1 (en) * | 2015-11-25 | 2017-05-25 | Camplex, Inc. | Surgical visualization systems and displays |
US9782604B2 (en) | 2005-04-14 | 2017-10-10 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy device and associated treatment method |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US10219944B2 (en) | 2014-09-09 | 2019-03-05 | LumiThera, Inc. | Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments |
US10231607B2 (en) | 2012-06-27 | 2019-03-19 | Camplex, Inc. | Surgical visualization systems |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10555728B2 (en) | 2012-06-27 | 2020-02-11 | Camplex, Inc. | Surgical visualization system |
US10568499B2 (en) | 2013-09-20 | 2020-02-25 | Camplex, Inc. | Surgical visualization systems and displays |
US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US10702353B2 (en) | 2014-12-05 | 2020-07-07 | Camplex, Inc. | Surgical visualizations systems and displays |
US10918455B2 (en) | 2017-05-08 | 2021-02-16 | Camplex, Inc. | Variable light source |
US10932766B2 (en) | 2013-05-21 | 2021-03-02 | Camplex, Inc. | Surgical visualization systems |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11154378B2 (en) | 2015-03-25 | 2021-10-26 | Camplex, Inc. | Surgical visualization systems and displays |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
CN116447567A (en) * | 2023-03-06 | 2023-07-18 | 广东光阳电器有限公司 | Myopia prevention and control eye-protection desk lamp and control method |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2668707C1 (en) * | 2018-02-15 | 2018-10-02 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method of laser treatment of macular edema which occurs after surgery for removal of lens |
RU2669858C1 (en) * | 2018-04-27 | 2018-10-16 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method of individual selection of energy parameters of micropulse mode on navilas 577s laser for treatment of central serous chorioretinopathy |
US10967197B2 (en) * | 2018-08-29 | 2021-04-06 | Azulite, Inc. | Phototherapy devices and methods for treating truncal acne and scars |
US11285335B2 (en) * | 2018-10-08 | 2022-03-29 | Biohacked, Inc. | Photo-therapeutic method and apparatus |
US20230248992A1 (en) * | 2022-02-09 | 2023-08-10 | Leticia Muss Ross | Portable High Power Photobiomodulation Device with Measuring Ring |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
US5259380A (en) * | 1987-11-04 | 1993-11-09 | Amcor Electronics, Ltd. | Light therapy system |
US5290272A (en) * | 1992-03-16 | 1994-03-01 | Helios Inc. | Method for the joining of ocular tissues using laser light |
US5533997A (en) * | 1994-06-29 | 1996-07-09 | Ruiz; Luis A. | Apparatus and method for performing presbyopia corrective surgery |
US5683436A (en) * | 1994-02-24 | 1997-11-04 | Amron Ltd. | Treatment of rhinitis by biostimulative illumination |
US5755752A (en) * | 1992-04-24 | 1998-05-26 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
US5766233A (en) * | 1994-01-20 | 1998-06-16 | Biolight Patent Holding Ab | Device for wound healing by means of light |
US5904678A (en) * | 1995-06-19 | 1999-05-18 | Lasersight Technologies, Inc. | Multizone, multipass photorefractive keratectomy |
US5964749A (en) * | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
US6238424B1 (en) * | 1996-06-07 | 2001-05-29 | Biolight Patent Holding Ab | Device for external treatment with pulsating light of high duty cycle |
US6274614B1 (en) * | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
US6287296B1 (en) * | 1995-11-30 | 2001-09-11 | Herbert Schwind Gmbh & Co. Kg | Device for the removal of tissue from the cornea of an eye |
US20020004673A1 (en) * | 1999-01-15 | 2002-01-10 | George Cho | Optical radiation treatment for enhancement of wound healing |
US20020087207A1 (en) * | 1999-01-15 | 2002-07-04 | George Cho | Optical radiation treatment for prevention of surgical scars |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US6471716B1 (en) * | 2000-07-11 | 2002-10-29 | Joseph P. Pecukonis | Low level light therapy method and apparatus with improved wavelength, temperature and voltage control |
US20030050674A1 (en) * | 2001-07-06 | 2003-03-13 | Joshi Ashok V. | Device and method for wound healing and infection control |
US6537302B1 (en) * | 1999-01-20 | 2003-03-25 | Biolight Patent Holding Ab | Means for external medical treatment by means of light |
US20030093135A1 (en) * | 2001-11-14 | 2003-05-15 | Healing Machines, Inc. | System and method for light activation of healing mechanisms |
US6607522B1 (en) * | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
US6677366B2 (en) * | 1997-02-11 | 2004-01-13 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
US6689124B1 (en) * | 1999-01-13 | 2004-02-10 | Biolight Patent Holding Ab | Device for controlling treatment administered externally with the aid of light |
US6811563B2 (en) * | 2003-01-09 | 2004-11-02 | Henry C. Savage, Jr. | Portable light delivery apparatus and methods for delivering light to the human body |
US7014639B2 (en) * | 2003-02-25 | 2006-03-21 | Skincare Technology, Inc. | Apparatus for aesthetic skin treatments |
US7118563B2 (en) * | 2003-02-25 | 2006-10-10 | Spectragenics, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
US7479136B2 (en) * | 2005-04-14 | 2009-01-20 | Dotson Robert S | Ophthalmic phototherapy treatment method |
US7914523B2 (en) * | 2004-02-06 | 2011-03-29 | Clinique Dr Daniel Barolet Inc. | Method for the treatment of mammalian tissues |
US8106038B2 (en) * | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0293126A1 (en) * | 1987-05-20 | 1988-11-30 | Keeler Limited | Photocoagulation apparatus |
CA1334399C (en) * | 1989-04-27 | 1995-02-14 | Murray M. Waldman | Therapeutic lamp |
US5520679A (en) | 1992-12-03 | 1996-05-28 | Lasersight, Inc. | Ophthalmic surgery method using non-contact scanning laser |
US5426662A (en) * | 1994-04-28 | 1995-06-20 | Coherent, Inc. | Laser system selectively operable at two competing wavelengths |
US6350275B1 (en) * | 1997-06-09 | 2002-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Devices for treating circadian rhythm disorders using LED's |
WO1999023524A1 (en) | 1997-10-30 | 1999-05-14 | The Microoptical Corporation | Eyeglass interface system |
US5997141A (en) * | 1998-03-06 | 1999-12-07 | Odyssey Optical Systems, Llc | System for treating the fundus of an eye |
RU2145247C1 (en) | 1998-04-10 | 2000-02-10 | Жаров Владимир Павлович | Photomatrix therapeutic device for treatment of extended pathologies |
US6019754A (en) | 1998-10-29 | 2000-02-01 | Kawesch; Glenn | Method and apparatus for improving lasik flap adherence |
US9192780B2 (en) * | 1998-11-30 | 2015-11-24 | L'oreal | Low intensity light therapy for treatment of retinal, macular, and visual pathway disorders |
US6676655B2 (en) * | 1998-11-30 | 2004-01-13 | Light Bioscience L.L.C. | Low intensity light therapy for the manipulation of fibroblast, and fibroblast-derived mammalian cells and collagen |
US6283956B1 (en) | 1998-11-30 | 2001-09-04 | David H. McDaniels | Reduction, elimination, or stimulation of hair growth |
US6887260B1 (en) | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
US6494878B1 (en) * | 2000-05-12 | 2002-12-17 | Ceramoptec Industries, Inc. | System and method for accurate optical treatment of an eye's fundus |
US6602275B1 (en) * | 2000-09-18 | 2003-08-05 | Jana Sullivan | Device and method for therapeutic treatment of living organisms |
US8308784B2 (en) | 2006-08-24 | 2012-11-13 | Jackson Streeter | Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease |
US7534255B1 (en) | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
US7303578B2 (en) | 2001-11-01 | 2007-12-04 | Photothera, Inc. | Device and method for providing phototherapy to the brain |
US20050159793A1 (en) * | 2002-07-02 | 2005-07-21 | Jackson Streeter | Methods for treating macular degeneration |
US7001413B2 (en) * | 2002-07-03 | 2006-02-21 | Life Support Technologies, Inc. | Methods and apparatus for light therapy |
US7201766B2 (en) * | 2002-07-03 | 2007-04-10 | Life Support Technologies, Inc. | Methods and apparatus for light therapy |
US6872221B2 (en) * | 2002-08-05 | 2005-03-29 | Larry Robert Lytle | Therapeutic low level laser apparatus and method |
JP2006501902A (en) * | 2002-10-03 | 2006-01-19 | ライト サイエンシズ コーポレイション | System and method for exciting photosensitive compounds in ocular tissue |
AU2003282929A1 (en) * | 2002-10-17 | 2004-05-04 | Iridex Corporation | Laser delivery device incorporating a plurality of laser source optical fibers |
US20040116909A1 (en) * | 2002-12-11 | 2004-06-17 | Ceramoptec Industries Inc. | Multipurpose diode laser system for ophthalmic laser treatments |
US7354432B2 (en) | 2003-01-17 | 2008-04-08 | Mcw Research Foundation, Inc. | Red to near-infrared photobiomodulation treatment of the visual system in visual system disease or injury |
US7344555B2 (en) | 2003-04-07 | 2008-03-18 | The United States Of America As Represented By The Department Of Health And Human Services | Light promotes regeneration and functional recovery after spinal cord injury |
CA2429906A1 (en) | 2003-05-28 | 2004-11-28 | Tony Mori | Controllable light therapy apparatus and method of treating with light therapy |
CA2533129A1 (en) * | 2003-07-31 | 2005-02-10 | Light Bioscience, Llc | System and method for the photodynamic treatment of burns, wounds, and related skin disorders |
US20050203592A1 (en) * | 2003-11-14 | 2005-09-15 | Klaus Teichert | Irradiation device and use thereof |
EP1748740A4 (en) * | 2004-04-09 | 2008-12-31 | Palomar Medical Tech Inc | Methods and products for producing lattices of emr-treated islets in tissues, and uses therefor |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20060235493A1 (en) | 2005-04-14 | 2006-10-19 | Dotson Robert S | Ophthalmic phototherapy device and associated treatment method |
US20130079759A1 (en) | 2005-04-14 | 2013-03-28 | Robert S. Dotson | Ophthalmic Phototherapy Device and Associated Treatment Method |
US20080269730A1 (en) | 2005-04-14 | 2008-10-30 | Dotson Robert S | Ophthalmic Phototherapy Device and Associated Treatment Method |
UA80467C2 (en) * | 2005-08-31 | 2007-09-25 | Leonid Andriiovych Lynnyk | Method and device for treating macular dystrophy |
US20070123844A1 (en) * | 2005-10-19 | 2007-05-31 | Shelly Henry | Method for treating ocular disorders |
US8251982B2 (en) | 2006-04-14 | 2012-08-28 | Asa S.R.L. | Laser apparatus for therapeutic applications |
US7758189B2 (en) * | 2006-04-24 | 2010-07-20 | Physical Sciences, Inc. | Stabilized retinal imaging with adaptive optics |
US20080009922A1 (en) * | 2006-05-25 | 2008-01-10 | Josef Bille | Photodynamic therapy for treating age-related macular degeneration |
CN101553244B (en) | 2006-07-21 | 2013-01-02 | 普罗米克斯有限公司 | Treatment for intimal hyperplasia and related conditions |
WO2008131343A1 (en) * | 2007-04-19 | 2008-10-30 | Mergenet Medical, Inc. | Temporal control in phototherapy |
CN105288619A (en) | 2008-04-04 | 2016-02-03 | 免疫之光有限责任公司 | Non-invasive systems and methods for in-situ photobiomodulation |
US20100079865A1 (en) | 2008-09-26 | 2010-04-01 | Nokia Corporation | Near-to-eye scanning display with exit-pupil expansion |
US8957835B2 (en) | 2008-09-30 | 2015-02-17 | Apple Inc. | Head-mounted display apparatus for retaining a portable electronic device with display |
US8582209B1 (en) | 2010-11-03 | 2013-11-12 | Google Inc. | Curved near-to-eye display |
US9711253B2 (en) | 2010-11-28 | 2017-07-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Method and system for electron radiotherapy |
US8508830B1 (en) | 2011-05-13 | 2013-08-13 | Google Inc. | Quantum dot near-to-eye display |
ES2560604T3 (en) | 2011-06-09 | 2016-02-22 | Deutsches Krebsforschungszentrum | Glycerol-3-phosphate dehydrogenase (GPD2) modulators for therapy |
US20130009853A1 (en) | 2011-07-05 | 2013-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Eye-glasses mounted display |
US8471967B2 (en) | 2011-07-15 | 2013-06-25 | Google Inc. | Eyepiece for near-to-eye display with multi-reflectors |
US8767305B2 (en) | 2011-08-02 | 2014-07-01 | Google Inc. | Method and apparatus for a near-to-eye display |
US8941560B2 (en) | 2011-09-21 | 2015-01-27 | Google Inc. | Wearable computer with superimposed controls and instructions for external device |
US20130088413A1 (en) | 2011-10-05 | 2013-04-11 | Google Inc. | Method to Autofocus on Near-Eye Display |
US8773599B2 (en) | 2011-10-24 | 2014-07-08 | Google Inc. | Near-to-eye display with diffraction grating that bends and focuses light |
US8705177B1 (en) | 2011-12-05 | 2014-04-22 | Google Inc. | Integrated near-to-eye display module |
US9291823B2 (en) | 2012-03-30 | 2016-03-22 | Google Inc. | Wearable device with input and output structures |
-
2008
- 2008-07-14 US US12/172,697 patent/US20080269730A1/en not_active Abandoned
-
2016
- 2016-03-25 US US15/081,805 patent/US9782604B2/en active Active
-
2017
- 2017-04-25 US US15/497,148 patent/US9814903B2/en active Active
- 2017-10-13 US US15/783,666 patent/US9974971B2/en active Active
-
2018
- 2018-04-19 US US15/957,496 patent/US10252078B2/en active Active
Patent Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5259380A (en) * | 1987-11-04 | 1993-11-09 | Amcor Electronics, Ltd. | Light therapy system |
US4930504A (en) * | 1987-11-13 | 1990-06-05 | Diamantopoulos Costas A | Device for biostimulation of tissue and method for treatment of tissue |
US5290272A (en) * | 1992-03-16 | 1994-03-01 | Helios Inc. | Method for the joining of ocular tissues using laser light |
US5755752A (en) * | 1992-04-24 | 1998-05-26 | Segal; Kim Robin | Diode laser irradiation system for biological tissue stimulation |
US5766233A (en) * | 1994-01-20 | 1998-06-16 | Biolight Patent Holding Ab | Device for wound healing by means of light |
US5683436A (en) * | 1994-02-24 | 1997-11-04 | Amron Ltd. | Treatment of rhinitis by biostimulative illumination |
US5533997A (en) * | 1994-06-29 | 1996-07-09 | Ruiz; Luis A. | Apparatus and method for performing presbyopia corrective surgery |
US5904678A (en) * | 1995-06-19 | 1999-05-18 | Lasersight Technologies, Inc. | Multizone, multipass photorefractive keratectomy |
US6387089B1 (en) * | 1995-09-15 | 2002-05-14 | Lumenis Ltd. | Method and apparatus for skin rejuvination and wrinkle smoothing |
US5964749A (en) * | 1995-09-15 | 1999-10-12 | Esc Medical Systems Ltd. | Method and apparatus for skin rejuvenation and wrinkle smoothing |
US6287296B1 (en) * | 1995-11-30 | 2001-09-11 | Herbert Schwind Gmbh & Co. Kg | Device for the removal of tissue from the cornea of an eye |
US6238424B1 (en) * | 1996-06-07 | 2001-05-29 | Biolight Patent Holding Ab | Device for external treatment with pulsating light of high duty cycle |
US6677366B2 (en) * | 1997-02-11 | 2004-01-13 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
US6274614B1 (en) * | 1997-02-11 | 2001-08-14 | Qlt Inc. | Methods, compositions and articles for reducing or preventing the effects of inflammation |
US6689124B1 (en) * | 1999-01-13 | 2004-02-10 | Biolight Patent Holding Ab | Device for controlling treatment administered externally with the aid of light |
US20020087207A1 (en) * | 1999-01-15 | 2002-07-04 | George Cho | Optical radiation treatment for prevention of surgical scars |
US20020004673A1 (en) * | 1999-01-15 | 2002-01-10 | George Cho | Optical radiation treatment for enhancement of wound healing |
US6537302B1 (en) * | 1999-01-20 | 2003-03-25 | Biolight Patent Holding Ab | Means for external medical treatment by means of light |
US6443976B1 (en) * | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
US6607522B1 (en) * | 2000-03-16 | 2003-08-19 | General Hospital Corporation | Methods for tissue welding using laser-activated protein solders |
US6471716B1 (en) * | 2000-07-11 | 2002-10-29 | Joseph P. Pecukonis | Low level light therapy method and apparatus with improved wavelength, temperature and voltage control |
US8106038B2 (en) * | 2001-02-15 | 2012-01-31 | Qlt Inc. | Method for reducing or preventing PDT related inflammation |
US20030050674A1 (en) * | 2001-07-06 | 2003-03-13 | Joshi Ashok V. | Device and method for wound healing and infection control |
US20030093135A1 (en) * | 2001-11-14 | 2003-05-15 | Healing Machines, Inc. | System and method for light activation of healing mechanisms |
US6811563B2 (en) * | 2003-01-09 | 2004-11-02 | Henry C. Savage, Jr. | Portable light delivery apparatus and methods for delivering light to the human body |
US7014639B2 (en) * | 2003-02-25 | 2006-03-21 | Skincare Technology, Inc. | Apparatus for aesthetic skin treatments |
US7118563B2 (en) * | 2003-02-25 | 2006-10-10 | Spectragenics, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
US7914523B2 (en) * | 2004-02-06 | 2011-03-29 | Clinique Dr Daniel Barolet Inc. | Method for the treatment of mammalian tissues |
US7479136B2 (en) * | 2005-04-14 | 2009-01-20 | Dotson Robert S | Ophthalmic phototherapy treatment method |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10485702B2 (en) | 2000-04-14 | 2019-11-26 | Glaukos Corporation | System and method for treating an ocular disorder |
US9993368B2 (en) | 2000-04-14 | 2018-06-12 | Glaukos Corporation | System and method for treating an ocular disorder |
US9572963B2 (en) | 2001-04-07 | 2017-02-21 | Glaukos Corporation | Ocular disorder treatment methods and systems |
US10828473B2 (en) | 2001-04-07 | 2020-11-10 | Glaukos Corporation | Ocular implant delivery system and methods thereof |
US9987472B2 (en) | 2001-04-07 | 2018-06-05 | Glaukos Corporation | Ocular implant delivery systems |
US10285856B2 (en) | 2001-08-28 | 2019-05-14 | Glaukos Corporation | Implant delivery system and methods thereof for treating ocular disorders |
US10485701B2 (en) | 2002-04-08 | 2019-11-26 | Glaukos Corporation | Devices and methods for glaucoma treatment |
US10252078B2 (en) | 2005-04-14 | 2019-04-09 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy method |
US9592405B2 (en) | 2005-04-14 | 2017-03-14 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy device and associated treatment method |
US9592404B2 (en) | 2005-04-14 | 2017-03-14 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy device and associated treatment method |
US9782604B2 (en) | 2005-04-14 | 2017-10-10 | Photospectra Health Sciences, Inc. | Ophthalmic phototherapy device and associated treatment method |
US9814903B2 (en) | 2005-04-14 | 2017-11-14 | Photospectra Health Services, Inc. | Ophthalmic phototherapy system and associated method |
US9974971B2 (en) | 2005-04-14 | 2018-05-22 | Photospectra Health Sciences, Inc | Ophthalmic phototherapy method |
US9962290B2 (en) | 2006-11-10 | 2018-05-08 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US20220211542A1 (en) * | 2010-09-30 | 2022-07-07 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US11033429B2 (en) * | 2010-09-30 | 2021-06-15 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US11135090B2 (en) * | 2010-09-30 | 2021-10-05 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US10285857B2 (en) | 2010-09-30 | 2019-05-14 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US11944573B2 (en) | 2012-03-26 | 2024-04-02 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US11197780B2 (en) | 2012-03-26 | 2021-12-14 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10271989B2 (en) | 2012-03-26 | 2019-04-30 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10092594B2 (en) | 2012-03-29 | 2018-10-09 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US10729716B2 (en) | 2012-03-29 | 2020-08-04 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US11931291B2 (en) | 2012-03-29 | 2024-03-19 | Epion Therapeutics, Inc. | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US11497766B2 (en) | 2012-03-29 | 2022-11-15 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
US10575986B2 (en) | 2012-03-29 | 2020-03-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
US9555111B2 (en) | 2012-03-29 | 2017-01-31 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
US11129521B2 (en) | 2012-06-27 | 2021-09-28 | Camplex, Inc. | Optics for video camera on a surgical visualization system |
US10555728B2 (en) | 2012-06-27 | 2020-02-11 | Camplex, Inc. | Surgical visualization system |
US11889976B2 (en) | 2012-06-27 | 2024-02-06 | Camplex, Inc. | Surgical visualization systems |
US11166706B2 (en) | 2012-06-27 | 2021-11-09 | Camplex, Inc. | Surgical visualization systems |
US10925589B2 (en) | 2012-06-27 | 2021-02-23 | Camplex, Inc. | Interface for viewing video from cameras on a surgical visualization system |
US10925472B2 (en) | 2012-06-27 | 2021-02-23 | Camplex, Inc. | Binocular viewing assembly for a surgical visualization system |
US10231607B2 (en) | 2012-06-27 | 2019-03-19 | Camplex, Inc. | Surgical visualization systems |
US11389146B2 (en) | 2012-06-27 | 2022-07-19 | Camplex, Inc. | Surgical visualization system |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10188551B2 (en) | 2013-03-15 | 2019-01-29 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10932766B2 (en) | 2013-05-21 | 2021-03-02 | Camplex, Inc. | Surgical visualization systems |
US11147443B2 (en) | 2013-09-20 | 2021-10-19 | Camplex, Inc. | Surgical visualization systems and displays |
US10881286B2 (en) | 2013-09-20 | 2021-01-05 | Camplex, Inc. | Medical apparatus for use with a surgical tubular retractor |
US10568499B2 (en) | 2013-09-20 | 2020-02-25 | Camplex, Inc. | Surgical visualization systems and displays |
US10219944B2 (en) | 2014-09-09 | 2019-03-05 | LumiThera, Inc. | Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments |
US10596037B2 (en) | 2014-09-09 | 2020-03-24 | LumiThera, Inc. | Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments |
US10881550B2 (en) | 2014-09-09 | 2021-01-05 | LumiThera, Inc. | Multi-wavelength phototherapy systems and methods for the treatment of damaged or diseased tissue |
US10702353B2 (en) | 2014-12-05 | 2020-07-07 | Camplex, Inc. | Surgical visualizations systems and displays |
US11154378B2 (en) | 2015-03-25 | 2021-10-26 | Camplex, Inc. | Surgical visualization systems and displays |
US20170143442A1 (en) * | 2015-11-25 | 2017-05-25 | Camplex, Inc. | Surgical visualization systems and displays |
US10966798B2 (en) * | 2015-11-25 | 2021-04-06 | Camplex, Inc. | Surgical visualization systems and displays |
US10918455B2 (en) | 2017-05-08 | 2021-02-16 | Camplex, Inc. | Variable light source |
US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
US11376040B2 (en) | 2017-10-06 | 2022-07-05 | Glaukos Corporation | Systems and methods for delivering multiple ocular implants |
USD901683S1 (en) | 2017-10-27 | 2020-11-10 | Glaukos Corporation | Implant delivery apparatus |
USD938585S1 (en) | 2017-10-27 | 2021-12-14 | Glaukos Corporation | Implant delivery apparatus |
USD846738S1 (en) | 2017-10-27 | 2019-04-23 | Glaukos Corporation | Implant delivery apparatus |
CN116447567A (en) * | 2023-03-06 | 2023-07-18 | 广东光阳电器有限公司 | Myopia prevention and control eye-protection desk lamp and control method |
Also Published As
Publication number | Publication date |
---|---|
US20180050221A1 (en) | 2018-02-22 |
US20170225012A1 (en) | 2017-08-10 |
US9974971B2 (en) | 2018-05-22 |
US9814903B2 (en) | 2017-11-14 |
US20160206897A1 (en) | 2016-07-21 |
US20180236258A1 (en) | 2018-08-23 |
US10252078B2 (en) | 2019-04-09 |
US9782604B2 (en) | 2017-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10252078B2 (en) | Ophthalmic phototherapy method | |
US9592405B2 (en) | Ophthalmic phototherapy device and associated treatment method | |
US7479136B2 (en) | Ophthalmic phototherapy treatment method | |
US20060235493A1 (en) | Ophthalmic phototherapy device and associated treatment method | |
EP2872082B1 (en) | Systems for corneal cross-linking with pulsed light | |
US20130245536A1 (en) | Systems and methods for corneal cross-linking with pulsed light | |
EP3009093B1 (en) | Laser system with short pulse characteristics and its methods of use | |
US20140066835A1 (en) | Systems and methods for corneal cross-linking with pulsed light | |
EP1896131B1 (en) | Use of electromagnetic radiation in the treatment of sensory organs | |
US20150088231A1 (en) | Ocular treatment system and method using red and gold phototherapy | |
WO2004053533A3 (en) | Multipurpose diode laser system for ophthalmic laser treatments | |
KR20050062597A (en) | Apparatus for performing photobiostimulation | |
JPH07236700A (en) | Rhinitis curing device | |
US10568691B2 (en) | Method and apparatus for stimulating cellulite reduction with femtosecond laser irradiation | |
US11420072B2 (en) | Method for increasing blood flow and metabolic rate of eye fundus | |
US20030078567A1 (en) | Method and apparatus for laser ThermoProtectiveTreatment(TPT) with pre-programmed variable irradiance long exposures | |
WO2014071408A1 (en) | Systems and methods for reshaping an eye feature | |
US20060084951A1 (en) | Low energy of excitation PDT compounds for treatment of ocular disease | |
TW202203869A (en) | A photo-biomodulation device with red light and near-infrared light for the eyes and the method thereof | |
JP2007517558A (en) | Apparatus and method for treating corneal neovascularization or vascular deposition on the conjunctiva |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: PHOTOSPECTRA HEALTH SCIENCES, INC., CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOTSON, ROBERT S;MERRY, GRAHAM;REEL/FRAME:031539/0280 Effective date: 20131026 |